Compare GROV & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | TARA |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0M | 165.5M |
| IPO Year | N/A | N/A |
| Metric | GROV | TARA |
|---|---|---|
| Price | $1.21 | $5.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.60 | ★ $20.40 |
| AVG Volume (30 Days) | 54.6K | ★ 1.3M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,808,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $2.77 |
| 52 Week High | $1.95 | $7.82 |
| Indicator | GROV | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 42.48 |
| Support Level | $1.22 | $5.03 |
| Resistance Level | $1.35 | $6.37 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 17.50 | 13.74 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).